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ABSTRACT: Bupropion and its three active metabolites exhibit clinical efficacy in the treatment of
major depression, seasonal depression and smoking cessation. The pharmacokinetics of bupropion in
humans is highly variable. It is not known if there are any non-reported metabolites formed in
humans in addition to the three known active metabolites. This paper reports newly identified and
non-reported metabolites of bupropion in human plasma samples. Human subjects were dosed with
a single oral dose of 75 mg of an immediate release bupropion HCl tablet. Plasma samples were col-
lected and analysed by LC–MS/MS at 0, 6 and 24 h. Two non-reported metabolites (M1 and M3)
were identified with mass-to-charge (m/z) ratios of 276 (M1, hydration of bupropion) and 258 (M3,
hydroxylation of threo/erythrohydrobupropion) from human plasma in addition to the known
hydroxybupropion, threo/erythrohydrobupropion and the glucuronidation products of the major
metabolites (M2 and M4–M7). These new metabolites may provide new insight and broaden the
understanding of bupropion’s variability in clinical pharmacokinetics. © 2016 The Authors
Biopharmaceutics & Drug Disposition Published by John Wiley & Sons Ltd.
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Introduction
Bupropion is prescribed for the treatment of major
depressive disorder, seasonal affective disorder
and smoking cessation [1–3]. It is reported that
bupropion is a non-selective inhibitor of the
dopamine and norepinephrine transporter as well
as an antagonist of the neuronal nicotinic acetyl-
choline receptor [4,5].
Bupropion is extensively metabolized to three
known active metabolites, hydroxybupropion
and the diasteroisomers threohydrobupropion
and erythrohydrobupropion. Using an animal
model it was shown that these metabolites may
exhibit as much as 25–50% potency compared
with the parent drug [6,7]. The metabolite
hydroxybupropion is formed by cytochrome
P450 2B6 (CYP2B6) while threo/erythro-
hydrobupropion are formed by carbonyl reduc-
tase (CR) [8–10]. It is reported that there are
multiple enzymes involved in the CR pathway
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including 11-β HSD and AKR7 family [8,11,12].
Both bupropion and its known major active
metabolites display long half-lives; bupropion
~21 h, hydroxybupropion ~20 h, and
threo/erythrohydrobupropion ~33–36 h [13].
Additionally, the Cmax of threohydrobupropion
and hydroxybupropion is ~3 and ~4–5 times
higher in plasma than that of bupropion,
respectively [13]. Recent reports show that the
major metabolites (hydroxybupropion and
threo/erythrohydrobupropion) undergo glucu-
ronidation [14].
About 87% of bupropion and its metabolites
are excreted in the urine where only 0.5% is
excreted unchanged, and 10% of bupropion is
eliminated in the feces where only 0.1% is
unchanged in humans after an oral dose [15,16].
However, one study investigated the elimination
and recovery of bupropion after a single oral
dose in urine from humans, where the data
indicated that bupropion comprised 0.6% and
hydroxybupropion comprised 2.8% of the total
recovery; in total these two analytes constituted
less than 3.4% of the total drug recovered [17].
Although threohydrobupropion or erythrohydro-
bupropion were not quantified in this study, their
abundance is usually lower than that of
hydroxybupropion [13,18]. The low recovery of
bupropion and hydroxybupropion suggests that
other metabolites might be formed. In addition,
the pharmacokinetics and efficacy of bupropion
is highly variable in clinical studies [18,19]. It is
suspected that other non-reported metabolites
may be formed. Since the three known major
metabolites are considered active, understanding
the metabolic pathway and discovery of new
metabolites may shed light on the variability of
pharmacokinetics and the efficacy of bupropion.
Healthy human subjects were administered a
single dose of immediate release bupropion HCl
(75 mg). Plasma samples were collected at 0, 6
and 24 h for analysis. To identify additional
metabolites, enhanced mass spectrometry (EMS),
multiple ion monitoring (MIM) and precursor
ion scans were used to analyse the plasma
samples. In all four subjects, M1–M7, were
identified in addition to the three major known
active metabolites. M1 is formed from the
hydration of the benzene ring of bupropion and
M3 results from further oxidation of
threo/erythrohydrobupropion or reduction of
hydroxybupropion. Both M1 and M3 have
unknown activity although it is possible that they
could be active. These data provide new insight
on bupropion’s metabolism in vivo, which may
contribute to its variability in pharmacokinetics
and efficacy. Further studies are warranted to




Bupropion HCl and venlafaxine HCl (internal
standard; IS) were purchased from Sigma (St
Louis, MO). Hydroxybupropion was purchased
from Cayman Chemicals (Ann Arbor, MI).
Threohydrobupropion and erythrohydrobu-
propion were purchased from Torando Chemical
Company (Torando, Canada). Methanol, LC–
MS/MS grade, was purchased from Fischer
Sciences (Hampton, NH).
Plasma sample extraction
All plasma samples were obtained in accordance
to the University of Michigan Institutional
Review Board (HUM00081894) and the Food &
Drug Administration Institutional Review
Board/ Research Involving Human Subjects
Committee (RIHSC #13-087D). Healthy partici-
pants voluntarily took a single dose of an imme-
diate release 75 mg of bupropion HCl tablet.
Blood samples were collected in EDTA K2
pretreated tubes from four participants at 0, 6
and 24 h, then immediately centrifuged at 4 °C
for 10 min at 14000 rpm. The plasma (superna-
tant) was then transferred to another cryogenic
tube and stored at 80 °C until analysis. Plasma
was diluted 1:3 in methanol and vortexed for
1 min. The samples were centrifuged at
14000 rpm for 10 min at 4 °C. The supernatant
was transferred to another tube and evaporated
using nitrogen gas and reconstituted in 120 μl
of 20% methanol in water. The samples were
then analysed by LC–MS/MS to monitor
metabolites.
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The LC–MS/MS analysis was conducted using a
Shimadzu SIL-20ACHT HPLC system coupled
with an API 4500 mass spectrometer (Applied
Biosystems, MDS Sciex Toronto, Canada),
equipped with an API electrospray ionization
(ESI) source. The LC–MS/MS (or LC–MS) was
operated at positive ESI ionization mode. The
Supelco C18 (150 × 4.6 mm i.d., 5 μm) column
was purchased from Sigma-Aldrich and used for
separation. The LC separation condition was opti-
mized with a blank plasma sample spiked with
bupropion and its three known metabolites. The
mobile phases consisted of 0.04% formic acid in
purified water (A) and 0.04% formic acid in meth-
anol (B). The gradient was run at 0–2 min 2% (B),
an increase to 32% (B) from 2–32 min, followed by
90% (B) at 32–36 min, and finally decreased back
to 2% (B) at 36–39.5 min with a flow rate of
1 ml/min. The EMS, the precursor ion scan and
the MIM scan were used as the survey scan to
identify the metabolites of bupropion. Either
information dependent acquisition (IDA) was
used to collect fragmentation of metabolite candi-
dates or single experiment of the enhanced prod-
uct ion scan (EPI) was applied to acquire
fragmentations of metabolites after running the
survey scan.
The ion spray voltage of QTrap (ABI) was set at
5500 V with a spray temperature of 600 °C, curtain
gas of 30 psi, gas 1 and gas 2 of 60 psi. The
declustering potential (DP) was set at 51 V. The
collision energy was kept at 5 eV for the survey
scan of EMS & MIM and 25 eV for the precursor
ion scan and EPI fragmentation.
Additionally, a more thorough analysis was
performed as described below to examine the iso-
topic patterns of the newly identified metabolites.
High resolution LC–MS analyses were performed
using an HPLC system (1200 series, Agilent
Technologies) coupled to a 6520 Accurate-Mass
Q-TOF (Agilent Technologies) operated in a posi-
tive electrospray ionization mode. The ESI condi-
tions were gas temperature 325 °C, drying gas
5 l/min, nebulizer 30 psig, fragmentor 150 V and
skimmer 65 V. The instrument was set to acquire
over the m/z range 50 to 3200 with an acquisition
rate of 2 spectra/s.
Data analysis
The analytical data were processed by the
software Analyst version 1.6.2 (Applied
Biosystems, Foster City, CA). The data were also
analysed in Lightsight version 2.3.0 (Applied
Biosystems). ChemBioDraw Ultra version 13.0
(CambridgeSoft) was used to draw structures.
Results
Bupropion and its metabolites
Figure 1 highlights the structures of the currently
known metabolites of bupropion (hydroxybu-
propion and threo/erythrohydrobupropion) and
seven metabolites identified in this study from
human plasma. Bupropion is metabolized by
both CYP2B6 and CR to form hydroxybupropion
and threo/erythrohydrobupropion, respectively
[8–10]. It is also known that threo/erythrohydro-
bupropion can further undergo glucuronidation
[20]. In addition to these metabolites, M1 and
M3 were detected in human plasma in this study
and are shown as non-reported metabolites.
Figure 2 illustrates the daughter ions of
bupropion (2A) and the daughter ions of three
known metabolites; hydroxybupropion (2B),
threohydrobupropion (2C) and erythrohydro-
bupropion (2C) that were acquired by direct MS
infusion using authentic standards. Threohydro-
bupropion and erythrohydrobupropion have the
same product ion spectra and fragments. The
fragmentation of bupropion and its three metabo-
lites were proposed based on their product ion
spectra. The characteristic daughter ions included
m/z ratios of 103, 131, 139, 151, 166, 167, 168, 184
and 238, which served as precursor ions for the
survey scan of the precursor ion scan.
Identification of non-reported bupropion’s
metabolites
Figure 3 indicates the extracted ion chromato-
grams of all metabolites detected in human
plasma after a single oral dose of bupropion.
Figure 3A shows the relative intensity and reten-
tion times for all metabolites detected, including
bupropion and the previous three known metabo-
lites in one MIM method after all survey scans
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were inspected. Figure 3B–E shows the extracted
ion chromatograms of seven metabolites detected
in plasma, corresponding to m/z ratios of (B) M1:
276, (C) M2: 432, (D) M3: 258, (E) M4–M7: 418.
The M1 metabolite elution was quite early. M2
andM3were eluted right after hydroxybupropion.
Multiple peaks with the same m/z = 418 were ob-
served (Figure 3E) and represented by M4, M5,
M6 and M7. These four peaks all had the same
product ion spectra, suggesting that stereochemis-
try might be involved. Together, the extracted ion
chromatogram results suggested seven metabo-
lites in addition to hydroxybupropion and threo/
erythrohydrobupropion.
Structure determination of new bupropion
metabolites
To determine the structures of the newly
identified metabolites, the product ion spectra
were evaluated (Figure 4). The m/z ratio of M1
(m/z = 276) increased 36 Daltons (Da) compared
with that of bupropion (m/z = 240). As shown in
Figure 4A, the fragments of the characteristic ions
that were consistent with bupropion were m/z
ratios of 167, 184 and 240. The M1 metabolite
was further investigated with a high resolution
mass spectrometer. The accurate mass (m/z) of
M1 that was measured was 276.1356 as shown in
Figure 5. This molecular ion also showed the char-
acteristic isotopic pattern of chlorine atoms. The
monoisotopic ion of 276 has an intensity three
times that of isotopic ion 278 as shown in
Figure 5, confirming the metabolite was indeed
real and not an artifact. The predicted formula
for this metabolite was C13H22ClNO3 with a mass
accuracy of 2 ppm, which contains four more
hydrogen atoms and two more oxygen atoms
than bupropion. These additional atoms were
assigned to the benzyl ring of bupropion as
shown in the proposed structure in Figure 4A.
M2 showed an m/z ratio of 432, which had
176 Da more than hydroxybupropion (Figure 4
B). In addition, its fragments contained the same
characteristic ions of 166, 184 and 256 as seen in
hydroxybupropion, suggesting glucuronidation
of hydroxybupropion.
M3 (m/z=258) increased in16Dacomparedwith
threo/erythrohydrobupropion and 18 Da more
than bupropion. The fragments of M3 (Figure 4C)
Figure 1. Bupropion and itsmetabolites found in humanplasma. Bupropion has been reported to bemetabolized by both CYP2B6 and
carbonyl reductase to form hydroxybupropion and threo/erythrohydrobupropion, respectively. Seven other metabolites were iden-
tified in human plasma after a single oral dose of bupropion; hydration of bupropion (M1), glucuronidation of hydroxybupropion
(M2), hydroxylation of threo/erythrohydrobupropion (M3) and glucuronidation of threo/erythrohydrobupropion (M4–M7)
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had the same characteristic ions as seen in
threo/erythrohydrobupropion; 151, 168 and 186.
The fragment of 186 corresponded to a loss of the
tert-butyl group and therefore no modification
could occur in the fragmented structure of 186. This
suggested that16Daaffected the tert-butylgroupof
threo/erythrohydrobupropion. The product ion of
m/z 240 of M3 confirmed this position. The 16 Da
increase was proposed as hydroxylation to
threo/erythrohydrobupropion. In Figure 3D, in
addition to the peak for M3, a large peak was
observedwith the sameparent ion of 258. This peak
eluted out earlier than M3 and at same retention
time as hydroxybupropion (22 min). The product
ion spectrum of this peak confirmed that it is the
hydroxybupropion isotopic ion containing 37Cl.
Finally, the lastmetabolitem/z= 418, had 176Da
more than threo/erythrohydrobupropion, and it
also had characteristic ions of m/z 151, 168 and
186 as seen in threo/erythrohydrobupropion,
Figure 2. Proposed fragmentation of bupropion and its metabolites. Authentic standards were directly infused to acquire product
ion spectra of (A) Bupropion (m/z 240); (B) Hydroxybupropion (m/z = 256); (C) Threo/Erythrohydrobuproprion (m/z = 242). The
structure indicates how these fragmentations occur on each molecule
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suggesting glucuronidation (Figure 4D). This
observation was consistent with Figure 3E produc-
ing four peaks. It can be postulated that two of
these peaks were from the conjugation of chiral
β-D glucuronic acid to a hydroxyl group of two
threohydrobupropion enantiomers, respectively,
and the other two were from the β-D glucuronic
acid conjugation of two erythrohydrobupropion
enantiomers, respectively. The conjugation of
chiral glucuronic acid introduced another chiral
center to the enantiomers and resulted in four
diasteroisomers. These conjugates could be sepa-
rated on the column showing four distinct peaks.
The isotopic distribution of three other metabo-
lites through EMS full scans with a narrow mass
range was also examined. As shown in Supple-
mentary Figure S1, mass spectra of M2, M3 and
M4–M7 all have a relative isotopic abundance of
35Cl and 37Cl, which further confirmed these three
metabolites came from bupropion.
Figure 3. Extracted ion chromatograms for bupropion metabolites found from human plasma. (A). All metabolites observed includ-
ing; hydroxybupropion (Hbup), threo/erythrohydrobupropion (TBUP/EBUP), and M1–M7; (B) M1 (m/z = 276); (C) M2 (m/
z = 432); (D) M3 (m/z = 258); (E) M4–M7 (m/z = 418). For the metabolites M4–M7, the same m/z value of 418 was observed
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Figure 4. Proposed fragmentation of bupropion metabolites found from human plasma. The spectra indicated the fragmentation of
each of the bupropion metabolites detected. Their structures were proposed: (A) M1, hydration of bupropion (m/z = 276); (B) M2,
glucuronidation of hydroxybupropion (m/z = 432); (C) M3, oxidation of threo/erythrohydrobupropion (m/z = 258); (D) M4,
glucuronidation of threo/erythrohydrobupropion (m/z = 418). M4–M7 have same product ion spectra, therefore only one spectrum
is shown here
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Relative quantification of new metabolites in
human plasma
To assess each metabolite formation in each sub-
ject at the two time points of 6 and 24 h, the peak
areas (counts) were compared (Figure 6). The peak
areas for each metabolite for the four subject sam-
ples are illustrated in Figure 6 by the m/z ratio.
The time points at 6 vs. 24 h were compared in or-
der to assess the relative amount of metabolite
formed. Over time, the majority of the metabolites
had a higher peak area at 6 h compared with at
24 h (Figure 6A–G). There were variations in the
peak area for each metabolite formation between
subjects, with M1 showing the largest variability.
However, these data suggest that all seven metab-
olites form in vivo.
Discussion
The biotransformation of bupropion involves
multiple enzymes that are expressed at different
levels in both the gastrointestinal tract and the
liver [21,22]. Since bupropion HCl is clinically
available in multiple formulations (immediate
release, sustained release or extended release) at
various doses (strengths 75–300 mg), it is likely
that these factors may influence the amount of
metabolites formed in the liver and gastroin-
testinal (GI) tract. Therefore, we intended to
investigate the complete biotransformation of
bupropion in vivo.
This study analysed human plasma after a
single oral dose of a 75 mg bupropion HCl tablet.
Seven metabolites were identified including two
non-reported metabolites for bupropion; hydra-
tion of bupropion (M1) and oxidation of
threo/erythrohydrobupropion (M3). Hydration
of bupropion was assigned to the benzyl ring of
bupropion since only the ring has unsaturated
bonds for the addition of hydrations (Figure 4A).
The fact that the retention time was much shorter
compared with the other metabolites of
bupropion provided evidence of the hydration of
bupropion, since more polar compounds typically
result in shorter retention times. Much to our
surprise, only one peak for hydroxylation of
threo/erythrohydrobupropion was observed
(M3). One explanation is that the second peak
was too low to observe, which seems sensible
considering how low the abundance of
erythrohydrobupropion is in human plasma. The
M4–M7 metabolites share the same m/z ratio
and fragmentation pattern, which indicates selec-
tive stereochemistry that is expected from the dia-
stereoisomers of threo/erythrohydrobupropion
through conjugation to β-D glucuronic acid. The
isotopic pattern of chlorine was used to distin-
guish the metabolite candidates that may have
been detected but were not a result of bupropion
metabolism [23]. Bupropion contains one chlorine
Figure 5. High resolution mass and isotopic pattern of newly found metabolite, m/z = 276. The predicated formula of this
metabolite is C13H22Cl NO3 with a mass accuracy of 2 ppm. The isotopic pattern of
35Cl and 37Cl offers strong evidence that this
metabolite is a product of bupropion
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atom on the benzyl ring, which assists in the
identification of metabolites from complex plasma
samples. The isotopic pattern of the chlorine atom
in Figure 5 clearly demonstrated that the new me-
tabolites are produced via biotransformation of
bupropion.
Gufford et al. has recently proposed several
UGT enzymes that might be responsible for the
formation of a glucuronidation metabolite for
bupropion, these same glucuronidation products
were consistent with what was observed in this
study [14]. However, the Gufford et al. study
analysed urine and not plasma. Therefore, M1 or
M3 may not have been excreted in urine or these
metabolites may not have been identified using
only multiple reaction monitoring (MRM). In ad-
dition to the MRM scanning method Gufford
et al. used, samples in this study also were tested
using a precursor ion scan, MIM and EMS,
allowing for the detection of M1 and M3.
Figure 6. Relative intensity of metabolites newly found in four human subjects. For comparison purposes, the peak area of each new
metabolite that formed in the plasma sample for each subject is shown at 6 h and 24 h. (A) M1 with m/z of 276; (B) M2 with m/z of
432; (C) M3 with m/z of 258 and (D) the sum of M4–M7 peak areas with m/z of 418
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While all seven metabolites formed in four dif-
ferent individuals, the peak area of these metabo-
lites varied quite a bit from individual to
individual. The known primary enzymes respon-
sible for the conversion of bupropion to form
hydroxybupropion and threo/erythrohydro-
bupropion are highly polymorphic. CYP2B6 can
have a 20–250 fold variability in terms of expres-
sion and activity and in addition is expressed at
different levels in multiple tissues, including the
GI tract and the liver [19,21,24–27]. Carbonyl
reductase enzymes have also been found to be
highly polymorphic with varying activity [28,29].
Similarly, studies have shown the uridine
5′-diphospho-glucuronosyltransferase (UGT) en-
zymes, which are responsible for glucuronidation
reactions, have high variability in terms of activ-
ity, which might lead to a functional impact
[30,31]. Therefore, it is reasonable to suspect that
polymorphs can explain the intersubject variabil-
ity observed amongst these four subjects.
Previous in vitro results have suggested that
other possible phase I metabolism enzymes might
be involved in the biotransformation of bupropion
and major metabolites, specifically hydroxy-
bupropion including: CYP2E1 CYP2C19 and
CYP3A4 in vitro [25,32,33], however, this has not
been explored in vivo. These phase I metabolism
enzymes may also be candidates for forming these
new metabolites. The metabolites identified in this
study may exhibit activity, however, further inves-
tigations would be necessary to determine if these
metabolites are indeed active. Nevertheless, the
identification of M1–M7 may shed light for the
further variability of bupropion in terms of
pharmacokinetics and efficacy.
Conclusion
Seven metabolites of bupropion in human plasma
samples were detected after a single dose of
bupropion HCl (IR 75 mg). Two non-reported
metabolites (M1 and M3) were identified with
mass-to-charge (m/z) ratios of 276 (M1, hydration
of bupropion) and 258 (M3, hydroxylation of
threo/erythrohydrobupropion) in addition to the
known hydroxybupropion, threo/erythrohydro-
bupropion and the glucuronidation products of
the major metabolites (M2 and M4–M7).
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Supporting Information
Additional supporting information may be found
in the online version of this article at the pub-
lisher’s web site:
Figure S1. Isotopic distribution of metabolites
newly found in human plasma. (A) M2 (m/
z = 432), (B) M3 (m/z = 258) and (C) M4 (m/
z = 418). M4 to M7 have the same isotopic pattern
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